Amanuel Yohannes Kehasse, PharmD, PhD
Assistant Professor, Medicine
Biography
Dr. Kehasse earned his Bachelor of Pharmacy degree (BPharm) from University of Asmara, College of Health Sciences in 2003 in Eritrea. Dr. Kehasse then joined the Orotta School of Medicine and served as an assistant lecturer of Biochemistry until 2005. At the same time, he served as the general secretary of Eritrean Pharmaceutical Association (EriPA). In 2005, he immigrated to the United States of America and earned his Doctor of Philosophy (PhD) in medical biochemistry from Boston University School of Medicine, Division of Graduate Medical Sciences in 2012. He then pursued his post-doctoral research fellowship at The Buck Institute -University of California San Francisco (UCSF). His research focused on post translational modification of proteins and biomarker discovery, and has published his research findings at American Journal of Pathology, Journal of Experimental Medicine and Oncotarget. In 2015, Dr. Kehasse became a registered pharmacist (RPh) in the State of Massachusetts. He then pursued his Pharmacy studies at Massachusetts College of Pharmacy and Health Sciences (MCPHS) and earned his Doctor of Pharmacy (PharmD) degree in 2017.
Education
- Boston University School of Medicine, PhD
- Massachusetts College of Pharmacy, PharmD
- University of Asmara, BPharm
Publications
- Published on 9/25/2024
Sacta MA, Sarvode S, Kehasse A, Mothi SS, Shah B, Sobota A. Adherence outcomes of a liquid hydroxyurea delivery program in a pediatric population. Pediatr Blood Cancer. 2024 Dec; 71(12):e31348. PMID: 39323047.
Read at: PubMed - Published on 11/23/2021
Zuckerman AD, DeClercq J, Choi L, Cowgill N, McCarthy K, Lounsbery B, Shah R, Kehasse A, Thomas KC, Sokos L, Stutsky M, Young J, Carter J, Lach M, Wise K, Thomas TT, Ortega M, Lee J, Lewis K, Dura J, Gazda NP, Gerzenshtein L, Canfield S. Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies. Am J Health Syst Pharm. 2021 Nov 23; 78(23):2142-2150. PMID: 34407179.
Read at: PubMed - Published on 4/22/2020
Bhat S, Kehasse A. Additional clinical pharmacists roles during COVID-19. J Am Coll Clin Pharm. 2020 Jun; 3(4):825. PMID: 32838216.
Read at: PubMed - Published on 5/18/2015
Lim HW, Kang SG, Ryu JK, Schilling B, Fei M, Lee IS, Kehasse A, Shirakawa K, Yokoyama M, Schnölzer M, Kasler HG, Kwon HS, Gibson BW, Sato H, Akassoglou K, Xiao C, Littman DR, Ott M, Verdin E. SIRT1 deacetylates ROR?t and enhances Th17 cell generation. J Exp Med. 2015 Jun 01; 212(6):973. PMID: 25987725.
Read at: PubMed - Published on 4/27/2015
Lim HW, Kang SG, Ryu JK, Schilling B, Fei M, Lee IS, Kehasse A, Shirakawa K, Yokoyama M, Schnölzer M, Kasler HG, Kwon HS, Gibson BW, Sato H, Akassoglou K, Xiao C, Littman DR, Ott M, Verdin E. SIRT1 deacetylates ROR?t and enhances Th17 cell generation. J Exp Med. 2015 May 04; 212(5):607-17. PMID: 25918343.
Read at: PubMed - Published on 7/15/2014
Wilson-Edell KA, Kehasse A, Scott GK, Yau C, Rothschild DE, Schilling B, Gabriel BS, Yevtushenko MA, Hanson IM, Held JM, Gibson BW, Benz CC. RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. Oncotarget. 2014 Jul 15; 5(13):5165-76. PMID: 24970821.
Read at: PubMed - Published on 10/1/2013
Kehasse A, Rich CB, Lee A, McComb ME, Costello CE, Trinkaus-Randall V. Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation. Am J Pathol. 2013 Dec; 183(6):1841-52. PMID: 24095926.
Read at: PubMed - Published on 3/1/2011
Boucher I, Kehasse A, Marcincin M, Rich C, Rahimi N, Trinkaus-Randall V. Distinct activation of epidermal growth factor receptor by UTP contributes to epithelial cell wound repair. Am J Pathol. 2011 Mar; 178(3):1092-105. PMID: 21356361.
Read at: PubMed